title: Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients.
authors.forename: Hideo
authors.initials: H
authors.lastname: Kudo
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Jinnin
authors.forename: Keitaro
authors.initials: K
authors.lastname: Yamane
authors.forename: Takamitsu
authors.initials: T
authors.lastname: Makino
authors.forename: Ikko
authors.initials: I
authors.lastname: Kajihara
authors.forename: Katsunari
authors.initials: K
authors.lastname: Makino
authors.forename: Noritoshi
authors.initials: N
authors.lastname: Honda
authors.forename: Wakana
authors.initials: W
authors.lastname: Nakayama
authors.forename: Satoshi
authors.initials: S
authors.lastname: Fukushima
authors.forename: Hironobu
authors.initials: H
authors.lastname: Ihn
mesh_terms: D000368:Aged; D016207:Cytokines / Q000097:blood / Q000378:metabolism*; D004311:Double-Blind Method; D015536:Down-Regulation / Q000187:drug effects*; D005260:Female; D005355:Fibrosis / Q000188:drug therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology* / Q000627:therapeutic use; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D040081:Protein Array Analysis; D012595:Scleroderma, Systemic / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D018417:Th1 Cells / Q000378:metabolism
chemical_list: D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors